TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

MABLINK

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

MABLINK

ST13

US500000079299550

Class

1, 5, 40, 42, 44

Filing

79299550

Registration

6532856

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

32

Latest update

04/28/2024

Classification

Registered

Trademark type

Word

Nice classes

1, 5, 40, 42, 44

Filing date

07/15/2020

Registration date

10/26/2021

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

10/26/2021

Last transaction

03/14/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

34

Owner location

FR

Examiner

PEISECKI, MARK

Law office

L50

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

M. B. (pessoa física)

Representatives

John R. Rudolph Eli Lilly and Company

Technical classification

Nice Classes

Class 1Class 5Class 40Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Chemical, biochemical, biological and biotechnological preparations for use in industry and science ; chemical substances for the manufacture of pharmaceutical products for non-medical purposes, namely, for use in manufacturing of antibody conjugates ; chemical substances for tethering molecules, in particular chemical substances for tethering molecules for cancer therapy, for research in active substances and medicines other than for medical or veterinary purposes; chemical substances for the formation of antibody conjugates for use in laboratories, other than for medical or veterinary purposes ; chemical reagents for scientific purposes other than for medical or veterinary purposes; reagents for scientific or medical research; chemical, biochemical and biological reagents for scientific or medical research use; chemicals for bioconjugation, reversible cysteine protection, surface modification, and the production of prodrugs for use in laboratories, other than for medical or veterinary purposes; antibodies and antibody conjugates for scientific purposes, other than for medical or veterinary purposes; antibodies for scientific or medical research; molecules and biomolecules, namely, reagents, antibody fragments, antibodies, all intended for fundamental research and development, medical research and scientific diagnosis; Diagnostic products for scientific or research use related to conjugated antibodies, namely, diagnostic preparations for scientific use

Class 5

Pharmaceutical preparations for the treatment of cancer ; pharmaceutical products for the prevention or treatment of human diseases, namely, the treatment of cancer; chemical, biological and biochemical products for medical and pharmaceutical use, namely, antibody-drug conjugates and any protein combined with a drug, a polynucleotide, another protein, a chemical entity, or another functional entity, and used as medical binders or fillers; pharmaceutical preparations, namely bioconjugates, intended for the diagnosis and treatment of diseases, namely, cancer ; antibody products, namely, antibody or protein bioconjugates for the medical diagnosis and treatment of cancer, namely, antibody/protein drug conjugates, antibody/protein labeled conjugates and antibody/protein imaging agent conjugates; delivery devices for antibodies, namely, drugs delivery agent in the form of antibodies drug conjugates that facilitate the delivery and action of medical preparations ; molecules and biomolecules, namely, reagents, antibody fragments, antibodies, all intended for medical diagnosis and disease treatment; pharmaceutical products, preparations and medical articles, namely, antibodies, antibody conjugates and active principles and antibody conjugates for medical purposes; chemical reagents for medical use, namely, chemical reagents to bind molecules for medical use; chemical reagents for the functionalization of biomolecules for medical use

Class 40

Preparation, transformation, processing of biopharmaceutical materials, reagents, antibodies and conjugated antibodies, namely, biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process; processing and transformation of biopharmaceuticals on behalf of third parties; custom manufacturing of scientific, medical, chemical, biochemical and pharmaceutical products, namely, conjugated antibodies and drug conjugate by biopharmaceutical compounders

Class 42

Scientific research; biological and chemical research; biochemical research and development; research and development in the pharmaceutical, biomedical and biotechnological fields, namely, research into antibodies, including conjugated antibodies; research and development in the fields of biological development and biomanufacturing; laboratory research, analysis, evaluation, development and clinical testing of therapeutic, preventive and diagnostic compositions and treatments; conducting scientific and medical research for third parties in the field of pharmaceuticals and cancer therapy ; consultancy in the field of pharmaceutical research, chemistry, biotechnology; Performance of chemical analyses, namely, custom synthesis of chemical substances; chemical and biological development services, namely custom design and development of chemical reagents and biochemical assays; services of a chemist and a biologist; scientific laboratory services namely chemical and biological laboratory services; scientific laboratory services, namely, laboratory services concerning the modification and production of reagents, antibodies and conjugated antibodies; scientific research and development services in the field of reagent development and production of antibodies and conjugated antibodies; conducting chemical and biological analyses; customized design and development of chemical reagents, antibodies and conjugated antibodies; development of chemical substances, namely, chemical substances to tether molecules and in particular technological platforms for the creation or improvement of antibody-drug conjugates or any protein combined with a drug, a polynucleotide, another protein, a chemical entity or another functional entity intended for industry and science

Class 44

Medical services; medical services, namely, medical modification of antibodies; medical services in the field of personalized medicine; medical advice and information services in the field of biopharmaceutical products; pharmaceutical advice; consultancy services in the field of medicine

Publications

History of USPTO decisions and trademark events.

32 publications found

NREP

NEW REPRESENTATIVE AT IB RECEIVED

04/28/2024

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

03/14/2024

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

03/14/2024

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

03/14/2024

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

03/14/2024

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

03/14/2024

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

05/09/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

04/18/2022

FIMP

FINAL DISPOSITION PROCESSED

04/18/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

01/26/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

10/26/2021

GPNX

NOTIFICATION PROCESSED BY IB

08/15/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

08/10/2021

PUBO

PUBLISHED FOR OPPOSITION

08/10/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

07/28/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

07/28/2021

NREP

NEW REPRESENTATIVE AT IB RECEIVED

07/23/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/21/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/05/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/24/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/24/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

06/24/2021

RFNT

REFUSAL PROCESSED BY IB

01/24/2021

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

01/05/2021

RFRR

REFUSAL PROCESSED BY MPU

01/05/2021

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

12/19/2020

CNRT

NON-FINAL ACTION WRITTEN

12/18/2020

DOCK

ASSIGNED TO EXAMINER

12/17/2020

MAFR

APPLICATION FILING RECEIPT MAILED

12/15/2020

DOCK

ASSIGNED TO EXAMINER

12/11/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/11/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

12/10/2020

Continuous trademark protection

Get notified about every new filing that threatens MABLINK or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.